World · English
US firm ArriVent’s plunge shows risks facing China’s biotech expansion into global markets
US firm ArriVent BioPharma’s shares plummeted after a late-stage trial failure involving a cancer drug licensed from China, a setback that analysts said highlighted the challenges facing Chinese biotech companies expanding overseas. New York-listed ArriVent closed down nearly 47 per cent on Tuesday after reporting that its cancer treatment firmonertinib failed to meet its main goal in a phase 3…
Read the full report at SCMP News →
About this page
AKHBAARI groups the same story across publishers so you can see who is reporting it and how they differ. The summary above is machine-generated from the publisher's own feed text and is labelled as such. The full report stays with the publisher, who holds copyright in it. See our editorial policy.